Cargando…
Immune-Based Combinations versus Sorafenib as First-Line Treatment for Advanced Hepatocellular Carcinoma: A Meta-Analysis
Recent years have observed the emergence of novel therapeutic opportunities for advanced hepatocellular carcinoma (HCC), such as combination therapies including immune checkpoint inhibitors. We performed a meta-analysis with the aim to compare median overall survival (OS), median progression-free su...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9858216/ https://www.ncbi.nlm.nih.gov/pubmed/36661706 http://dx.doi.org/10.3390/curroncol30010057 |
_version_ | 1784874043750481920 |
---|---|
author | Rizzo, Alessandro Ricci, Angela Dalia Fanizzi, Annarita Massafra, Raffaella De Luca, Raffaele Brandi, Giovanni |
author_facet | Rizzo, Alessandro Ricci, Angela Dalia Fanizzi, Annarita Massafra, Raffaella De Luca, Raffaele Brandi, Giovanni |
author_sort | Rizzo, Alessandro |
collection | PubMed |
description | Recent years have observed the emergence of novel therapeutic opportunities for advanced hepatocellular carcinoma (HCC), such as combination therapies including immune checkpoint inhibitors. We performed a meta-analysis with the aim to compare median overall survival (OS), median progression-free survival (PFS), complete response (CR) rate, and partial response (PR) rate in advanced HCC patients receiving immune-based combinations versus sorafenib. A total of 2176 HCC patients were available for the meta-analysis (immune-based combinations = 1334; sorafenib = 842) and four trials were included. Immune-based combinations decreased the risk of death by 27% (HR, 0.73; 95% CI, 0.65–0.83; p < 0.001); similarly, a PFS benefit was observed (HR, 0.64; 95% CI, 0.5–0.84; p < 0.001). In addition, immune-based combinations showed better CR rate and PR rate, with ORs of 12.4 (95% CI, 3.02–50.85; p < 0.001) and 3.48 (95% CI, 2.52–4.8; p < 0.03), respectively. The current study further confirms that first-line immune-based combinations have a place in the management of HCC. The CR rate observed in HCC patients receiving immune-based combinations appears more than twelve times higher compared with sorafenib monotherapy, supporting the long-term benefit of these combinatorial strategies, with even the possibility to cure advanced disease. |
format | Online Article Text |
id | pubmed-9858216 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-98582162023-01-21 Immune-Based Combinations versus Sorafenib as First-Line Treatment for Advanced Hepatocellular Carcinoma: A Meta-Analysis Rizzo, Alessandro Ricci, Angela Dalia Fanizzi, Annarita Massafra, Raffaella De Luca, Raffaele Brandi, Giovanni Curr Oncol Systematic Review Recent years have observed the emergence of novel therapeutic opportunities for advanced hepatocellular carcinoma (HCC), such as combination therapies including immune checkpoint inhibitors. We performed a meta-analysis with the aim to compare median overall survival (OS), median progression-free survival (PFS), complete response (CR) rate, and partial response (PR) rate in advanced HCC patients receiving immune-based combinations versus sorafenib. A total of 2176 HCC patients were available for the meta-analysis (immune-based combinations = 1334; sorafenib = 842) and four trials were included. Immune-based combinations decreased the risk of death by 27% (HR, 0.73; 95% CI, 0.65–0.83; p < 0.001); similarly, a PFS benefit was observed (HR, 0.64; 95% CI, 0.5–0.84; p < 0.001). In addition, immune-based combinations showed better CR rate and PR rate, with ORs of 12.4 (95% CI, 3.02–50.85; p < 0.001) and 3.48 (95% CI, 2.52–4.8; p < 0.03), respectively. The current study further confirms that first-line immune-based combinations have a place in the management of HCC. The CR rate observed in HCC patients receiving immune-based combinations appears more than twelve times higher compared with sorafenib monotherapy, supporting the long-term benefit of these combinatorial strategies, with even the possibility to cure advanced disease. MDPI 2023-01-05 /pmc/articles/PMC9858216/ /pubmed/36661706 http://dx.doi.org/10.3390/curroncol30010057 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Systematic Review Rizzo, Alessandro Ricci, Angela Dalia Fanizzi, Annarita Massafra, Raffaella De Luca, Raffaele Brandi, Giovanni Immune-Based Combinations versus Sorafenib as First-Line Treatment for Advanced Hepatocellular Carcinoma: A Meta-Analysis |
title | Immune-Based Combinations versus Sorafenib as First-Line Treatment for Advanced Hepatocellular Carcinoma: A Meta-Analysis |
title_full | Immune-Based Combinations versus Sorafenib as First-Line Treatment for Advanced Hepatocellular Carcinoma: A Meta-Analysis |
title_fullStr | Immune-Based Combinations versus Sorafenib as First-Line Treatment for Advanced Hepatocellular Carcinoma: A Meta-Analysis |
title_full_unstemmed | Immune-Based Combinations versus Sorafenib as First-Line Treatment for Advanced Hepatocellular Carcinoma: A Meta-Analysis |
title_short | Immune-Based Combinations versus Sorafenib as First-Line Treatment for Advanced Hepatocellular Carcinoma: A Meta-Analysis |
title_sort | immune-based combinations versus sorafenib as first-line treatment for advanced hepatocellular carcinoma: a meta-analysis |
topic | Systematic Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9858216/ https://www.ncbi.nlm.nih.gov/pubmed/36661706 http://dx.doi.org/10.3390/curroncol30010057 |
work_keys_str_mv | AT rizzoalessandro immunebasedcombinationsversussorafenibasfirstlinetreatmentforadvancedhepatocellularcarcinomaametaanalysis AT ricciangeladalia immunebasedcombinationsversussorafenibasfirstlinetreatmentforadvancedhepatocellularcarcinomaametaanalysis AT fanizziannarita immunebasedcombinationsversussorafenibasfirstlinetreatmentforadvancedhepatocellularcarcinomaametaanalysis AT massafraraffaella immunebasedcombinationsversussorafenibasfirstlinetreatmentforadvancedhepatocellularcarcinomaametaanalysis AT delucaraffaele immunebasedcombinationsversussorafenibasfirstlinetreatmentforadvancedhepatocellularcarcinomaametaanalysis AT brandigiovanni immunebasedcombinationsversussorafenibasfirstlinetreatmentforadvancedhepatocellularcarcinomaametaanalysis |